Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 13, 2026 17:00 ET | Source: XORTX Therapeutics Inc.

XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset

• VB4-P5 – novel new chemical entity with potential to address significant unmet need in rare and large-market chronic kidney disease • CALGARY, Alberta, April 13, 2026 (GLOBE NEWSWIRE) -- XORTX...
April 01, 2026 13:00 ET | Source: XORTX Therapeutics Inc.

XORTX Confirms Effective Date of Share Consolidation

CALGARY, Alberta, April 01, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
March 26, 2026 18:00 ET | Source: XORTX Therapeutics Inc.

XORTX Announces Results of Annual and Special Meeting of Shareholders

CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
March 26, 2026 16:32 ET | Source: XORTX Therapeutics Inc.

XORTX Announces Change of Effective Date of Share Consolidation

CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
March 25, 2026 18:15 ET | Source: XORTX Therapeutics Inc.

XORTX Announces Share Consolidation

CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
March 24, 2026 17:00 ET | Source: XORTX Therapeutics Inc.

XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting

CALGARY, Alberta, March 24, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
March 18, 2026 07:00 ET | Source: XORTX Therapeutics Inc.

XORTX Announces Substitute Director Nominees for its Upcoming Annual and Special Meeting of Shareholders

CALGARY, Alberta, March 18, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...
March 13, 2026 07:00 ET | Source: XORTX Therapeutics Inc.

XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share Consolidation

Your vote is important – Vote well in advance of the proxy voting deadline: March 20, 2026XORTX’s board of directors unanimously recommends that Shareholders vote FOR all resolutionsShareholder...
March 05, 2026 07:00 ET | Source: XORTX Therapeutics Inc.

XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders

CALGARY, Alberta, March 05, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
February 04, 2026 18:00 ET | Source: XORTX Therapeutics Inc.

XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

CALGARY, Alberta, Feb. 04, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company...